Laura C. A. Galbraith

TL;DR: It is demonstrated that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.

TL;DR: It is shown that BRAF mutant melanoma cells that have developed acquired resistance to BRAF inhibitors display increased oxidative metabolism and increased dependency on mitochondria for survival, suggesting that targeting specific metabolic pathways may offer exciting therapeutic opportunities to treat resistant tumors, or to delay emergence of resistance in the first‐line setting.

TL;DR: It is shown that elevated levels of PPARG strongly correlate with elevation of FASN in human CaP and that high levels ofPPARG/FASN and PI3K/pAKT pathway activation confer a poor prognosis, and it is suggested that CaP patients could be stratified in terms of PP ARG/ fasN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARg/FasN inhibition.

TL;DR: There is growing evidence implicating the role of obesity and peri‐prostatic adipose tissue (PPAT) in PC aggressiveness and related mortality, suggesting the importance of lipid pathways in both localised and disseminated disease.

TL;DR: Fundamental insights are reported into the validity, reliability and clinical feasibility of using heterogeneous Pd catalysts as implantable devices to accurately activate chemotherapy within a tumour.